c-Src antisense complexed with PAMAM denderimes decreases of c-Src expression and EGFR-dependent downstream genes in the human HT-29 colon cancer cell line

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 5, 2012, Pages 2235-2240

  Nourazarian, Ali Reza ^a   Pashaei Asl, Roghiyeh ^b   Omidi, Yadollah ^b,c   Najar, Ahmad Gholamhoseinian ^d  

^a KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antisense; c Src; Human colon cancer; PAMAM dendrimer

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BIOMATERIAL; DENDRIMER; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; NANOPARTICLE; PAMAM STARBURST; PROTEIN KINASE P60;

ARTICLE; CELL PROLIFERATION; COLON TUMOR; DRUG ANTAGONISM; GENETICS; HUMAN; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

BIOCOMPATIBLE MATERIALS; BLOTTING, WESTERN; CELL PROLIFERATION; COLONIC NEOPLASMS; DENDRIMERS; HUMANS; NANOPARTICLES; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS PP60(C-SRC); REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84872678180     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.5.2235     Document Type: Article

References (30)

1. Baker JR, Bielinska AU, Kukowska-Latallo JF (2004). Dendrimer-mediated cell transfection in vitro. Methods Mol Biol, 245, 67-82.
2. Chapnick DA, Warner L, Bernet J, et al (2011). the TGF beta and MAPK pathways in cancer progression. Cell Biosci, 1, 42.
3. Chua W, Kho PS, Moore MM, Charles KA, Clarke SJ (2011). Clinical, laboratory and molecular factors predicting chemotherapy efficacy and toxicity in colorectal cancer. Crit Rev Oncol Hematol, 79, 224-50.
4. Eichman JD, Bielinska AU, Kukowska-Latallo JF, Baker JR (2000). The use of PAMAM Denderimes in the efficienttransfer of genetic material into cells. Pharm Sci Technolo Today, 3, 232-45.
5. Ellis LM, Staley CA, Liu W, et al (1998). Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src. J Biol Chem, 273, 1052-7.
6. Green DW, Roh H, Pippin JA, Drebin JA (2001). Beta-catenin antisense treatment decreases beta-catenin expression and tumor growth rate in colon carcinoma xenografts. J Surg Res, 101, 16-20.
7. Greenlee RT, Murray T, Bolden S, Wingo PA (2000). Cancer statistics. CA Cancer J Clin, 50, 7-33.
8. Irby RB, Yeatman TJ (2000). Role of Src expression and activation in human cancer. Oncogene, 19, 5636-42.
9. Kumar R, Srinivasan S, Pahari P, Rohr J, Damodaran C (2010). Activating stress-activated protein kinase-mediated cell death and inhibiting epidermal growth factor receptor signaling: a promising therapeutic strategy for prostate cancer. Mol Cancer Ther, 9, 2488-96.
10. Lieu C, Kopetz S (2010). The SRC family of protein tyrosine kinases: a new and promising target for colorectal cancer therapy. Clin Colorectal Cancer, 9, 89-94.
11. Mao W, Irby R, Coppola D, et al (1997). Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential. Oncogene, 15, 3083-90.
12. Midgley R, Kerr D (1999). colorectal cancer. Lancet, 353, 391-9.
13. Bradford MM (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem, 72, 248-54.
14. Mukhopadhyay D, Tsiokas L, Zhou XM, et al (1995). Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature, 375, 577-81.
15. Nakhlband A, Barar J, Bidmeshkipour A, Heidari HR, Omidi Y (2010). Bioimpacts of anti epidermal growth factor receptor antisense complexed with polyamidoamine dendrimers in human lung epithelial adenocarcinoma cells. J Biomed Nanotechnol, 6, 360-9.
16. Orava EW, Cicmil N, Gariepy J (2010). Delivering cargoes into cancer cells using DNA aptamers targeting internalized surface portals. Biochim Biophys Acta, 1798, 2190-200.
17. Rubenstein M, Tsui P, Guinan P (2010). Treatment of MCF-7 breast cancer cells employing mono- and bispecific antisense oligonucleotides having binding specificity toward proteins associated with autocrine regulated growth and BCL-2. Med Oncol, 25, 182-6.
18. Kopetz S (2007). Targeting SRC and epidermal growth factor receptor in colorectal cancer: rationale and progress into the clinic. Gastrointest Cancer Res, 1, 37-41.
19. Raymond WR (2007). Cancer Biology. 4th ed. Michigan1: University of Michigan Medical School Ann Arbor.
20. Siegel R, Naishadham D, Jemal A (2012). Cancer statistics. CA Cancer J Clin, 62, 10-29.
21. Staley CA, Parikh NU, Gallick GE (1997). Decrasesd tumorigenicity of a human colon adenocarcinoma cell line by an antisense expression vector specific for c-Src. Cell Growth Differ, 8, 269-74.
22. Summy JM, Gallick GE (2003). Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev, 22, 337-58.
23. Summy JM, Trevino JG, Lesslie DP, et al (2005). AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes. Mol Cancer Ther, 4, 1900-11.
24. Talamonti MS, Roh MS, Curley SA, Gallick GE (1993). Increase in activity and level of pp60c-src in progressive stages of human colorectal cancer. J Clin Invest, 91, 53-60.
25. Termuhlen PM, Curley SA, Talamonti MS, Saboorian MH, Gallick GE (1993). Site-specific differences in pp60c-src activity in human colorectal metastases. J Surg Res, 54, 293-8.
26. Wang P, Zhao XH, Wang ZY, et al (2010). Generation 4 polyamidoamine dendrimers is a novel candidate of nano-carrier for gene delivery agents in breast cancer treatment. Cancer Lett, 298, 34-49.
27. Windham TC, Parikh NU, Siwak DR, et al (2002). Src activation regulates anoikis in human colon tumor cell lines. Oncogene, 21, 7797-807.
28. Xiong H, Su WY, Liang QC, et al (2009). Inhibition of STAT5 induces G1 cell cycle arrest and reduces tumor cell invasion in human colorectal cancer cells. Lab Invest, 89, 717-25.
29. Yamaguchi M, Tanaka T, Waki M, et al (1997). Antisense src expression inhibits tyrosine phosphorylation of Shc and its association with Grb2 and Sos which leads to MAP kinase activation in U937 human leukemia cells. Leukemia, 11, 497-503.
30. Yavari K, Taghikhani M, Maragheh MG, Mesbah-Namin SA, Babaei MH (2009). Knockdown of IGF-IR by RNAi inhibits SW480 colon cancer cells growth in vitro. Arch Med Res, 40, 235-40.